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Importance of inflammatory mechanism in therapeutic effect of 
hypothermia on stroke
Jung Ho Lee
Department of Medical Science,
The Graduate School, Yonsei University
(Directed by Professor Chul Hoon Kim)
In ischemic stroke, the inflammatory response plays an important role in infarct 
evolution and in the overall severity. Therapeutic hypothermia is a promising 
neuroprotectant, but the mechanisms underlying this neuroprotection are unknown. 
High mobility group B1 (HMGB1) is a critical mediator in many human diseases. 
Previous studies showed that HMGB1 induces the inflammatory response in in vitro
and in vivo stroke model. I hypothesized that hypothermia reduces HMGB1 release 
and inhibits its effect in activation of the inflammatory response to ischemic injury. 
2Rats underwent middle cerebral artery occlusion with or without hypothermia. In 
middle cerebral artery occlusion model rats, hypothermia greatly reduced the infarct 
size. Immunofluorescence and enzyme linked immunosorbent assay showed that 
hypothermia inhibited extracellular HMGB1 release from the ischemic brain into 
systemic circulation. By real time PCR, I showed that hypothermia reduced the 
expressions of infarct-modifying inflammatory cytokines, such as interleukin (IL)-
1β, IL-6, and tissue necrosis factor (TNF)-α, in peri-ischemic and ischemic regions. 
When glycyrrhizin, a direct HMGB1 binding inhibitor was injected, similar effects 
were also observed in our animal stroke model with hypothermia. In conclusion, I 
have demonstrated that hypothermia inhibits the release of HMGB1 and reduces the 
inflammatory responses of the penumbra; I suggested that the inhibition of HMGB1 
release via hyporthermia in the brain provides an important mechanism underlying 
neuroprotective effects on ischemic and peri-ischemic regions in stroke.
Key words: stroke, hypothermia, inflammation, cytokine
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Ⅰ. INTRODUCTION
Ischemic stroke causes brain damage and significant chronic disability. The 
ischemic penumbra is the region that surrounds the ischemic core. If a therapeutic 
intervention fails, the ischemic penumbra can also be recruited into the ischemic
core. Thus, the penumbra is an important target for stroke therapeutics. Ischemic 
stroke induces an innate immune response. High mobility group box protein 1 
(HMGB1) is one of the most important mediators of this innate immune response.
Previous studies showed that HMGB1 induces the inflammatory response and 
4brain damage in in vitro and in vivo model. Therapeutic hypothermia is one of the 
most effective neuropretectant. Although, there is no consensus regarding which 
hypothermia-supressed inflammatory mediator generates the neuroprotection. I
designed this study to investigate the mechanism by which hypothermia reduces 
the inflammatory response in acute ischemic stroke. The current study suggests 
that therapeutic hypothermia inhibits the ischemic brain damage propagation by 
inhibiting HMGB1 release.
1. Stroke
Stroke, also known as cerebrovascular disease, is caused by the interruption or 
severe reduction of the blood flow to a brain region. Cerebrovascular disease 
includes two types of disease: ischemic stroke and hemorrhagic stroke. Ischemic 
stroke accounts for nearly 90 % of stroke cases. When an intracranial vessel is
occluded, the brain regions supplied by that vessel become deprived of oxygen and 
glucose. If blood flow is not restored within 10 min, cell death can occur in the 
poorly supplied brain region. Patients may experience various neurological 
symptoms, including paralysis, impaired speech, and loss of vision. Neurons, the 
most important cell type in the brain do not recover after damage from ischemic 
injury. Therefore, when therapeutic strategies fail to block the ischemic damage, 
stroke patients show poor neurological outcomes.1 Societal and economic burden 
for the treatment and the rehabilitation of stroke patients is great. Acute ischemic 
stroke is a leading cause of mortality and serious long-term disability worldwide.2
Clear elucidation of the damaging mechanisms of stroke and developing 
therapeutics for effective treatment are important for human health.
52. Ischemic penumbra
A. The definition and meaning of ‘ischemic penumbra’ in ischemic stroke
The ischemic penumbra is the target region for stroke therapeutics; Astrup et al. 
first defined this region in 1981.3 According to the original definition, the ischemic 
penumbra is the brain region with reduced cerebral blood flow surrounding the 
infarct core. The penumbra shows an impaired neuronal functionality, but a 
preserved structural integrity. If the therapeutic approach for blocking the 
ischemic damage fails, the ischemic penumbra may be recruited into the 
developing infarct core. This is an important characteristic of the penumbra in 
stroke therapeutics. Thus, saving the penumbral region is the prime purpose of 
stroke therapeutics.
B. Biologic markers for ischemic penumbra
Although many researchers have conducted multiple studies regarding the 
penumbra, there is no definite histologic marker for the penumbral region.4
Researchers are now developing histological markers that clearly show the 
penumbral region under experimental conditions. Perfusion-diffusion mismatch is 
the most widely used method for detection of the penumbra through magnetic 
resonance imaging (MRI) in stroke patients and experimental ischemic stroke 
models. Perfusion-diffusion mismatch is defined as the mismatch between the 
volume of abnormal tissue in perfusion-weighted MRI images and that in 
diffusion-weighted MRI images. Perfusion-diffusion mismatch region shows 
decreased cerebral blood flow but no detectable brain damage. Perfusion-
6diffusion mismatch is typically presumed to represent the penumbra, but there are 
several limitations.5,6 Abnormality in perfusion-weighted imaging can 
overestimate the infarct region, and the initial diffusion lesion does not 
necessarily show or encompass the irreversible infarct region. Hence, in order to 
evaluate the effects of potential therapeutics in animal stroke models, researchers 
want to have histologic markers for the penumbra.
3. Recombinant tissue plasminogen activator
Recombinant tissue plasminogen activator (tPA) is the only FDA-approved 
therapeutic for stroke patients. tPA reestablishes blood flow and saves damaged 
brain regions by breaking down a vessel-occluding thrombi. The National 
Institute of Neurological Disorders and Stroke (NINDS) tPA Stroke Study 
reported that intravenous tPA treatment showed a clear benefit versus placebo in 
stroke patients.7 However, tPA treatment usage is limited by this important 
disadvantage: it is beneficial only when treatment is delivered within 3~4.5 hr 
after the onset of symptom. This “time is brain” concept reflects that the 
aggravation of damage by ischemia and reperfusion is time-sensitive and phase 
specific. Consequently, less than 10 % of patients with acute ischemic stroke are 
candidates for thrombolysis.8 tPA treatment can also induce intracerebral 
hemorrhage in stroke patients.9 Development of new adjunctive therapies 
targeting neuroprotection beyond thrombolysis is needed to attenuate the brain 
ischemic injury.
74. Inflammation
A. Beneficial and detrimental effects of inflammation
Inflammation is important for the survival of organisms. Inflammatory 
mechanisms protect organisms from injury and infection, which are major threats 
in evolution. When pathogens from the external environment enter an organism, 
the organism senses those pathogens and induces controlled responses to remove 
the pathogens. Under these circumstances, well-controlled inflammatory 
responses are beneficial for the host defense and tissue repair. However, when 
inflammation becomes chronic or excess, inflammatory mechanism is detrimental.
Chronic or excess inflammatory mechanisms are important mediators in the 
pathophysiology of many human diseases.10
B. Mechanisms of ischemic damage
After the onset of blood flow reduction, the ischemic damage occurs by many 
important mechanisms.11 In the acute phase, blood flow decreases and a ionic
disturbance occurs. Intracellular calcium levels elevate; then the glutamate release 
from brain cells increases and the elevation of extracellular glutamate level 
induces the cytotoxicity. Cytotoxic edema and necrosis occur within a few hours 
of ischemia. In the subacute phase (hours and days from the onset of ischemic 
injury), neuronal apoptosis occurs and reactive oxygen species are produced; 
monocytes, macrophage, and neutrophils induce inflammatory responses. After 
weeks or months, necrotic debris is removed and new vessels are formed. Lost 
circuits are re-connected and neurovascular remodeling and functional recovery 
occur.
8C. Inflammatory mechanisms in stroke
Inflammatory response has a prominent role in stroke pathophysiology. Many 
types of inflammatory cells and mediators are shown to have negative roles in 
ischemic brain injury. Among these, pro-inflammatory cytokines are important 
mediators in ischemic damage. Interleukin (IL)-1β, IL-6, tissue necrosis factor 
(TNF)-α are representative examples of stroke-related cytokines.12,13 Inhibiting 
the action of these cytokines yields protective effects on the infarct size and 
several subsequent damaging mechanisms of stroke. Inhibition of these cytokines 
by neutralizing antibodies or newly developed pharmacological inhibitor is a 
potential candidate therapy for stroke patients.
Cerebral ischemic injury is highly associated with extreme inflammatory 
responses and the neuronal cell loss. Ischemic insult is sterile injury that activates
innate immunity, which induces a devastating inflammation in the absence of 
foreign invaders.14,15 In these sterile injuries, high mobility group box protein-1 
(HMGB1) is an important mediator.
5. High Mobility Group Box protein-1 (HMGB1)
A. Extracellular HMGB1 acts as a pro-inflammatory cytokine
HMGB1 was first discovered as a nuclear non-histone DNA binding protein. For 
decades, HMGB1 was known merely as a structural protein related to the stability 
of DNA and a transcriptional modulation. However, in 1999, HMGB1 was 
identified as a late mediator in endotoxin lethality.16 HMGB1 is released by two 
different mechanisms. Active release of HMGB1 occurs when immunologically 
competent cells (i.e., monocytes and macrophages) are activated during infection 
9by pathogens or toxins. Active release of HMGB1 generally occurs within 24 to 
48 hr after the infective threat. Passive release of HMGB1 occurs when cells are 
damaged by the necrotic injury; HMGB1 is passively released a few minutes after 
the onset of the sterile injury, which includes the ischemic injury. Contrary to its 
role in the nucleus, after active or passive release, HMGB1 acts as a pro-
inflammatory cytokine. While HMGB1 propagates signals through many types of 
receptors, the two most important receptors in the pathophysiology of human 
disease are toll-like receptor (TLR) 4 and receptor for advanced glycation end-
product (RAGE). In monocytes and macrophages, HMGB1-TLR4 signaling 
induces an elevated pro-inflammatory cytokine expression by the nuclear 
translocation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB).17,18 In endothelial cells and immune cells, HMGB1 effects cell 
migration, cell growth, and the differentiation through RAGE signaling.19,20 The 
exact signaling pathway of HMGB1-RAGE signaling is elusive until now. 
HMGB1 has a pivotal role in inflammatory responses through these receptors.
B. HMGB1 in stroke patients and stroke animal models
In many human diseases including sepsis, arthritis, and myocardial infarction, 
HMGB1 induces inflammatory response and tissue damage. In one clinical study, 
Goldstein et al.21 revealed that serum HMGB1 levels are significantly elevated 
(218.0 ± 18.4 ng/ml) in patients with acute ischemic stroke within 24 hr after the 
onset of symptoms compared to those of healthy controls (16.8 ± 10.9 ng/ml) (p <
0.001), and this elevation is correlated with the length of time after the onset of 
symptom. Higher plasma HMGB1 levels are a valuable prognostic marker for 
mortality and neurologic outcomes in ischemic stroke.22 Other previous studies 
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reported elevated serum HMGB1 levels after ischemic injury by MCAO.23,24
These studies show that HMGB1 may be important mediator in stroke.
C. The role of HMGB1 in stroke pathophysiology
The role of HMGB1 in ischemic brain damage has been established partly by in 
vivo and in vitro studies. Kim et al.25 demonstrated that extracellular HMGB1 
released from injured neurons in post-ischemic brain activates microglia, 
astrocytes, and microvascular endothelial cells. Actively secreted HMGB1 from 
these cells expands the brain inflammatory response and significantly aggravates
brain damage.25-27 HMGB1 also has an effect on the systemic inflammatory 
response after brain ischemic injury.28 HMGB1 induces complex behavior 
sickness syndrome in a mouse model, and inhibits adaptive immune responses by 
the induction of bone marrow egression and the proliferation of bone marrow-
derived suppressor cells.28 HMGB1 functionally exhausts mature monocytes and 
induces lymphopenia. HMGB1 is an important mediator in immune suppression 
after extensive ischemia and its mechanisms are detrimental in stroke prognosis. 
Although many negative roles of HMGB1 in stroke are well known, there are 
discrepancies regarding the effect of HMGB1 inhibition via antibodies on infarct 
size of stroke animal models. In one study, the injection of HMGB1 monoclonal 
antibodies before MCAO reduced the size of the infarct region.29 Conversely, in 
another study using MCAO mouse model, there was no significant change on 
infarct size after the injection of neutralizing HMGB1 antibody.28
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6. Therapeutic hypothermia
A. Therapeutic hypothermia is a promising neuroprotectant
Lowering body temperature to preserve tissue in various medical conditions is 
not a new concept. Indeed, hypothermia has been used as a therapeutic agent for 
millennia.30 Although therapeutic hypothermia has been shown to be a robust 
neuroprotectant for brain injury,30 its use for acute ischemic stroke has been 
limited due to incomplete clinical data. However, after two clinical studies 
demonstrated the benefit of therapeutic hypothermia in patients with cardiac 
arrest, hypothermia has been clinically applied during post-resuscitation care as 
an efficient therapy for improving neurologically intact tissue.31,32 The current 
guidelines recommend that therapeutic hypothermia (cooling the core temperature 
to 32°C or 34°C) for 12 to 24 hr should be considered for comatose adult patients 
after cardiac arrest.33
B. The mechanisms of neuroprotection in therapeutic hypothermia in 
stroke
Many studies have suggested several mechanisms of the neuroprotective effect 
of therapeutic hypothermia in various time phases of stroke.11 In the acute phase, 
therapeutic hypothermia increases cerebral blood flow,34 reduces glutamate 
release,35 improves glucose metabolism within brain cells,36 and alters immediate 
early gene expressions and cellular stress responses.37 In the subacute phase of 
stroke, hypothermia protects brain cells from apoptotic cell death by the reduction 
of pro-apoptotic protein expressions (e.g., BAX) and increasing anti-apoptotic 
protein expression (e.g., BCL-2).38 Hypothermia also inhibits caspase-dependent 
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pathways and extrinsic apoptotic pathways.39 Additionally, the inflammatory 
responses are inhibited by therapeutic hypothermia during the subacute phase. 
Inflammatory cell infiltration is reduced in the infarct region,40 transcriptional 
activation of immune-related genes is inhibited by hypothermia,41 and radical 
oxygen production is reduced.42 The disruption of the blood-brain barrier can 
induce inflammatory competent cell infiltration (neutrophil, T cell) into infarct 
region. Hypothermia inhibits blood-brain barrier disruption by reducing 
extracellular protease activity.43-45 In the chronic phase, hypothermia induces the 
remodeling process of the infarct region and enhances precursor cell 
differentiation. Hypothermia also induces angiogenesis, neurite outgrowth, and
neuronal connectivity.46,47 As described above, therapeutic hypothermia has 
protective effects by many putative mechanisms. A better understanding of these 
hypothermic mechanisms can open new avenue for stroke research, and it can 
also improve identifying proper indications for introducing hypothermia to stroke
patients. Once the mechanisms of hypothermic neuroprotective effects are well 
elucidated, new adjunctive hypothermic therapeutics may be easily developed 
around that mechanism. However, yet, there is no consensus regarding which 
hypothermia-suppressed inflammatory mediator generates the most protection.
7. Aims of the study
The aim of this study was to investigate the neuroprotective effects of 
therapeutic hypothermia on post-ischemic inflammation in a clinically relevant 
MCAO rat model. As HMGB1 exerts its effect as the trigger and booster of 
inflammatory responses in the ischemic injury, therapeutic hypothermia may 
contribute to the inhibition of HMGB1 release from brain cells. However, to my 
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knowledge, no study has determined whether HMGB1 release from ischemic 
cortex cells is inhibited by hypothermia, or found the consequence of reduced 
extracellular HMGB1 after brain ischemia. I hypothesized that the protective 
mechanism of therapeutic hypothermia on the post-ischemic brain injury after 
MCAO is inhibition of extracellular HMGB1 release, which mitigates its pro-
inflammatory role in the acute stage of ischemia.
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Ⅱ. MATERIALS AND METHODS
1. Animal preparation
Healthy male Wistar rats weighing between 295-315 g were used for all 
experiments. A single-source breeder (Orientbio Inc., Seongnam, Korea) 
consistently supplied healthy animals with uniform age and weight. All animal 
experiments were approved by Institutional Animal Care and Use Committee 
(IACUC) of Yonsei University Health System. Prior to experimentation, rats were 
offered food and water ad libitum.
2. Experimental model of MCAO
The rats were subjected to permanent MCAO, as described previously.48
Previously established rodent model of focal brain ischemia with MCAO by 
intraluminal suture was used.49 Anesthesia was induced with 5 % isoflurane in 
mixture of 0.7 L/min nitrous oxide and 0.3 L/min oxygen. During the surgical 
procedure for MCAO, anesthesia was maintained using 1~2 % isoflurane with the 
aforementioned gas mixture. Rectal temperature was monitored and maintained 
with surface cooling ice packs, a temperature monitoring system, and a feedback-
controlled heating pad (Harvard apparatus, Holliston, MA, USA). Under an 
operating microscope, the left common carotid artery (CCA) was carefully exposed 
by dissection through a midline neck incision. The ligation and coagulation of the 
external carotid artery (ECA) was performed after isolation of the ECA and its 
branches. The internal carotid artery (ICA) was carefully isolated from the adjacent 
vagus nerve. After ligation of the pterygopalatine artery, the CCA also was ligated 
with 6-0 black silk. Next, the proximal portion of the ICA was loosely tied with 6-0 
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black silk, and a microvascular clip was clipped across the distal portion of the ICA. 
After making an incision with micro-scissors in the proximal ICA, the intraluminal 
4-0 MCAO suture (Doccol Corporation, Sharon, MA, USA) was inserted in a hole, 
and loosely tied 6-0 black silk was tightened on the proximal portion of the ICA. 
After removing the microvascular clip, the intraluminal 4-0 MCAO suture was 
advanced approximately 22 mm beyond the CCA bifurcation from the proximal 
ICA lumen to the distal direction. After sham and MCAO surgeries, tracheostomy 
was performed with an intravenous catheter (IV Catheter 16G, Sewoon Medical Co.,
Seoul, Korea) through a midline neck incision, and mechanical ventilation (tidal 
volume, 3.0 ml; respiratory rate, 80/min) was conducted using a rodent ventilator 
(SAP-830/AP, CWE, Inc., Ardmore, PA, USA). The incision was closed by simple 
suture technique with 4-0 nylon.
3. Experiment protocol and temperature management
First, the animals were randomly divided into four groups: sham+normothermia
(n = 11), sham+hypothermia (n = 12), MCAO+normothermia (n = 15), and 
MCAO+hypothermia (n = 12). In hypothermia groups, surface cooling started after 
15 min of ischemia (maintaining at 33.0 ± 0.5°C) by placing ice packs on the torso 
of rats. Vecuronium (0.9 mg/kg) was injected intramuscularly after mechanical 
ventilation to inhibit shivering. After sham and MCAO operations, the target core 
temperature was carefully monitored and maintained for 4 hr using feedback-
controlled heating pads and surface cooling with ice packs. In the normothermia and 
hypothermia groups, targeted core temperatures were maintained at 37.5 ± 0.5°C
and 33.0 ± 0.5°C, respectively. During the experiments, all animals were treated in 
the same manner, except for the hypothermia and MCAO. Figure 1A shows the 
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experimental protocol.
Second, the pharmacological direct inhibitor against HMGB1 (glycyrrhizin) was 
used to demonstrate the functional significance of HMGB1 release in ischemic 
injury. Animals were randomly divided into four groups: sham+vehicle (n = 7), 
sham+glycyrrhizin (n = 7), MCAO+vehicle (n = 9), and MCAO+glycyrrhizin    
(n = 9). A mixture of glycyrrhizin (100 mg/kg) and 5 ml of saline was injected 
intraperitoneally 30 min before MCA occlusion. All groups were treated similarly 
throughout the experiment with the exception of intraperitoneal injection for the 
glycyrrhizin groups and MCA occlusion for the MCAO groups.
Third, HMGB1 neutralizing antibody was injected by intracerebroventricular route. 
Five μg of antibody in 5 μl of phosphate buffered saline was injected 30 min before 
MCA occlusion by infusion pump. Two groups were treated similarly throughout 
the experiment with the exception of antibody injection.
4. Infarct volume measurement
Rats were decapitated under anesthesia 4 hr after MCA occlusion or sham 
operation. Whole brains were dissected and sliced into 2 mm thick coronal sections 
using a matrix device (ASI instrument, Warren, MI, USA). Coronal sections were 
stained with 1 % TTC (2, 3, 5-triphenyl-tetrazolium chloride, Sigma-Aldrich, St. 
Louis, MO, USA) solution (in saline) at 37°C for 10 min. After staining, sections 
were immersed in 4 % paraformaldehyde solution (in phosphate-buffered saline) 
and fixed for 18 hr. After fixation, the caudal face of each section was scanned with 
a flatbed scanner (EPSON, Nagano, Japan). The scanned image was analyzed with 
ImageJ 1.48v software (National Institutes of Health, Bethesda, MD, USA). The 
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white regions in the ipsilateral hemisphere were measured as the infarcted area 
using an auto-threshold ImageJ method.50 Infarct volumes (mm3) were calculated by 
multiplying the summed section of the white areas by the section thickness.
5. Enzyme-linked immunosorbent assay (ELISA)
A 23 gauge needle was inserted into the right atrium at 4 hr post MCA occlusion or 
sham operation. Approximately 1 ml of blood was withdrawn and collected with a 
serum separator tube (BD Vacutainer® SST™ Advance, BD, Plymouth, UK). To 
separate serum, collected blood was centrifuged for 20 min at 2000 rpm and    
serum was stored at -80°C. HMGB1 concentration was determined using the 
HMGB1 ELISA kit (IBL international GMBH, Hamburg, Germany).
6. Immunofluorescence
For immunofluorescence, 2 mm thick rat brain slices (bregma 0.7 mm to -1.3 mm) 
were immersed in a 4 % paraformaldehyde solution, and then subjected to 
cryoprotection by 30 % sucrose in phosphate-buffered saline. The slice was frozen 
with optical cutting temperature (OCT) compound (CellPath, Mid Wales, UK), then 
cryosections were cut at a thickness of 20 μm in a cryostat machine (Leica 
Biosystems, Buffalo Grove, IL, USA). Sections from 0.2 mm to -0.3 mm relative to 
bregma were chosen for staining. Sections were first permeabilized with PBS 
containing 0.3 % Triton X-100, 3 % goat serum, 0.02 % sodium azide, 10 mg/ml
bovine serum albumin (BSA) for 1 hr and incubated overnight at 4°C with anti-
HMGB1 polyclonal antibody (1:100, ab18256; Abcam, Cambridge, UK) in PBS 
containing 3 % goat serum, 0.02 % sodium azide, 10 mg/ml BSA. Next, sections 
were washed with PBS for 5 min, three times, and incubated for 1 hr at room 
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temperature with Alexa 566 conjugated goat anti-rabbit antibody (1:500, Invitrogen). 
Then sections were washed with PBS three times and mounted using Vectashield 
with DAPI solution (Vectorlab, Burlingame, CA, USA). Slides were observed under 
a confocal microscope (LSM 700, Carl Zeiss GmbH, Jena, Germany). TTC staining 
results showed the lower half of the primary somatosensory cortex and the 
secondary somatosensory cortex in the left hemisphere of each rat were damaged by 
MCA occlusion; these regions are observed as the ischemic regions. The 
corresponding regions in the right hemisphere were defined as the contralateral 
regions.
7. Real-time polymerase chain reaction (PCR)
Three regions of rat brain tissue from each brain slice (bregma -1.3 mm to -3.3 mm) 
were used for the real-time PCR experiments. All TTC stating results showed 
infarcted ipsilateral primary sensory cortex barrel field regions. This region was 
defined as the ischemic region. TTC results showed the ipsilateral primary and 
secondary motor cortices and cingulate cortex were not infarcted, but rather 
adjacent to the infarcted region. This region was chosen as the peri-ischemic region. 
Contralateral primary sensory cortex barrel field region tissue was used as the 
control region. Tissue RNA was extracted using a Hybrid-R kit (Geneall 
biotechnology, Seoul, Korea). cDNA was prepared from 1 μg of RNA with a 1st 
strand cDNA Synthesis Kit (Takara bio, Shiga, Japan). Specific PCR primers for IL-
1α, IL-β, IL-6, TNF-α were designed from corresponding mRNA sequences using 
Primer Express 3.0 software (Applied Biosystems, Foster city, CA, USA). PCR 
amplification was performed on an ABI 7300 system (Applied Biosystems, Foster 
city, CA, USA) and involved the use of SYBR Premix Ex Taq (Takara, Shiga, 
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Japan).
8. Statistical analysis
All data are presented as mean ± s.e.m. Differences between groups were 
analyzed with one-way analyses of variance (ANOVA) followed by Bonferroni post 
hoc test for multiple comparisons between groups. Values of p < 0.05 were 
considered significant.
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Ⅲ. RESULTS
1. Therapeutic hypothermia was successfully induced and maintained in the 
MCAO model
All experiments were conducted according to the schedule schematically 
illustrated in Figure 1A. Focal brain ischemia was induced by MCAO through 
intraluminal suture. After MCAO, therapeutic hypothermia was applied to the 
MCAO rat model and core temperature of 33.0 ± 0.5°C was maintained for the next 
4 hr (Figure 1B). In normothermia groups, normothermia was maintained by a 
temperature monitoring system and feedback-controlled heating pad. After 4 hr, rats 
were sacrificed and samples for further molecular studies were prepared.
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Figure 1. Induction and maintenance of hypothermia in MCAO model rats. (A) 
Illustration that schematically shows schedule of experiments. (B) Monitored traces 
of rectal temperature of rats in experiments. (MCAO: middle cerebral artery 
osslucion)
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2. Therapeutic hypothermia descreases infarct volume of post-ischemic brain
To evaluate the neuroprotective effects of mild hypothermia on post-ischemic 
brain, infarct volumes of MCAO+hypothermia group rats were compared with those 
of MCAO+normothermia group rats by TTC staining.
The infarct volumes in the ischemic hemispheres of the MCAO-treated rats were 
much larger than those of control (sham-operated) rats and hypothermia-only 
treated rats. Mean infract volumes were evaluated at 4 hr of ischemia; the 
administration of mild hypothermia (33°C) significantly decreased the mean infarct 
volumes (73.60 ± 37.67 mm3, n = 4) of MCAO rats compared with those of the 
MCAO+normothermia group (256.40 ± 29.01 mm3, n = 4, p < 0.001) (Figure 2A 
and B). This MCAO model results indicate that mild hypothermia treatment has 
protective effects in the acute stage (4 hr after onset of MCAO) of ischemic injury.
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Figure 2. Reduction of infarct volume of post-ischemic brain by hypothermia. (A) 
Representative pictures of TTC staining results. (B) Quantification plot for infarct 
volume measured in TTC-stained brain slices of rat treated with MCAO and/or 
hypothermia. Number of rats in each group is as follows. Sham+normothermia   
(n = 3), sham+hypothermia (n = 4), MCAO+normothermia (n = 5), 
MCAO+hypothermia (n = 4). ### p < 0.001 versus non-MCAO, non-hypothermia 
group, *** p < 0.001, MCAO without hypothermia group versus MCAO with 
hypothermia group, one-way ANOVA followed by Bonferroni post hoc test.
3. Hypothermia inhibits the extracellular release of HMGB1 from the 
ischemic cortex
To address whether hypothermia inhibits the extracellular release of HMGB1 after 
ischemic injury, immunofluorescence was used to compare the amounts of nuclear 
HMGB1 in the brains of MCAO- and hypothermia- treated rats with those of 
MCAO-only treated rats.
When ischemic injury is achieved using MCAO, HMGB1, which is usually 
located in the nucleus, is released from most cortical cells.27 A prior study showed 
that HMGB1 immunoreactivity was markedly reduced in the ischemic cortex.27 In 
immunofluorescence, therapeutic hypothermia significantly attenuated the 
extracellular release of HMGB1 on the post-ischemic rat cortex, compared with 
ischemic regions that showed a reduced number of HMGB1-positive cortical cells 
(Figure 3A and B).
The percentage of HMGB1 positive cells/DAPI positive cells was 30.31 ± 1.60 % in 
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the cortex of the ischemic hemisphere versus 65.04 ± 3.53 % in the corresponding 
cortical region of the hypothermia-treated ischemic hemisphere (p < 0.001). 
These results indicate that hypothermia has strong inhibitory effects on the release 
of HMGB1 from the ischemic cortex in ischemic injury.
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Figure 3. Hypothermia inhibits the reduction of the number of cells with nuclear 
HMGB1 immunoreactivity in post-ischemic brain. (A) Immunofluorescence 
staining result of MCAO- and/or hypothermia-treated rat brain. (B) Quantification 
plot of immunofluorescence results. Number of rats in each group is as follows. 
Sham+normothermia (n = 4), sham+hypothermia (n = 4), MCAO+normothermia 
(n = 6), MCAO+hypothermia (n = 4). ### p < 0.001 versus non-MCAO, non-
hypothermia group, *** p < 0.001, MCAO without hypothermia group versus 
MCAO with hypothermia group, one-way ANOVA followed by Bonferroni post hoc
test.
4. HMGB1 is released preferentially from neurons and hypothermia inhibits 
this release
Rat brain sections were immunostained with HMGB1 and NeuN, a widely used 
neuronal marker, to identify which cell type is important in HMGB1 release and 
whether hypothermia has an effect on the release of HMGB1 by this cell type.
In immunofluorescence analysis, HMGB1 was depleted in the ischemic cortex, 
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consistent with my previous immunofluorescence results in Figure 3 (Figure 4A and 
B). The percentage of HMGB1-positive cells that colocalized with the neuronal 
marker NeuN was reduced to 39.0 ± 3.1 % in rat brains after MCAO ischemic 
injury (Figure 4B). Treatment of hypothermia attenuates the reduction of the 
percentage of HMGB1-positive cells that is colocalized with the NeuN in MCAO 
rat brains (Figure 4B).
These results indicate that HMGB1 is preferentially released from neurons and that 
hypothermia inhibits this release.
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Figure 4. . Hypothermia inhibits the reduction of the percentage of HMGB1-
positive cells with NeuN immunoreactivity in post-ischemic brain. (A) 
Representative immunofluorescence pictures. (B) Quantification plot of 
immunofluorescence results. Number of rats in each group is as follows. 
Sham+normothermia (n = 4), sham+hypothermia (n = 3), MCAO+normothermia
(n = 5), MCAO+hypothermia (n = 3). ### p < 0.001 versus non-MCAO, non-
hypothermia group, *** p < 0.001, MCAO without hypothermia group versus 
MCAO with hypothermia group, one-way ANOVA followed by Bonferroni post hoc
test.
5. Therapeutic hypothermia reduces MCAO-induced elevation of serum 
HMGB1 
To evaluate the effect of hypothermia on the release of HMGB1 into circulation, I 
measured serum HMGB1 level with an ELISA assay. The ELISA results showed 
that HMGB1 was significantly elevated in the serum of rats after receiving ischemic 
injury by MCAO. However, therapeutic hypothermia significantly inhibited the 
elevation of serum HMGB1 levels after ischemic insult, returning the levels to a 
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normal physiological range (Figure 5).
These results indicate that therapeutic hypothermia has an inhibitory effect on the 
extracellular release of HMGB1 from post-ischemic brain cells into the circulatory 
system.
Figure 5. Hypothermia inhibits the elevation of serum HMGB1 level in MCAO-
treated rat model. Number of rats in each group is as follows. Sham+normothermia 
(n = 4), sham+hypothermia (n = 4), MCAO+normothermia (n = 4), 
MCAO+hypothermia (n = 4). ### p < 0.001 versus non-MCAO, non-hypothermia 
group, *** p < 0.001, MCAO without hypothermia group versus MCAO with 
hypothermia group, one-way ANOVA followed by Bonferroni post hoc test.
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6. Glycyrrhizin, a pharmacological HMGB1 inhibitor, ameliorates MCAO-
induced brain ischemic injury
To further demonstrate that HMGB1 plays a direct and critical role in brain 
ischemic injury, I examined the effects of glycyrrhizin as a pharmacological 
HMGB1 inhibitor, which directly inhibits HMGB1 actions in post-ischemic injury.
I first asked whether inhibition of HMGB1 action by glycyrrhizin has an effect on 
the size of ischemic damage. Infarct volumes of vehicle-treated MCAO rats and 
those of MCAO+glycyrrhizin group rats were measured. The inhibition of HMGB1 
activity using glycyrrhizin markedly attenuated the infarct volumes of the post-
ischemic cortex in MCAO-treated rats (257.20 ± 21.93 mm3 in vehicle-treated 
MCAO group versus 77.35 ± 27.19 mm3 in the glycyrrhizin-treated MCAO group) 
(Figure 6A and B). This result indicates that extracellular HMGB1 plays a direct 
and critical role in aggravation of ischemic injury. 
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Figure 6. Glycyrrhizin reduces infarct volume in post-ischemic brain. (A) 
Representative pictures of TTC staining results. (B) Quantification plot of TTC 
results. Number of rats in each group is as follows. Sham+vehicle (n = 4), sham+ 
glycyrrhizin (n = 4), MCAO+vehicle (n = 5), MCAO+glycyrrhizin (n = 5). ###    
p < 0.001 versus non-MCAO, non- glycyrrhizin group, *** p < 0.001, MCAO 
without glycyrrhizin group versus MCAO with glycyrrhizin group, one-way 
ANOVA followed by Bonferroni post hoc test. 
7. Glycyrrhizin inhibits HMGB1 release from the ischemic cortex
Next, I wanted to discern the effect of glycyrrhizin on extracellular release of 
HMGB1 from brain cells. 
Using immunofluorescence, the nuclear HMGB1 immunoreactivity of post-
ischemic brains of MCAO- and glycyrrhizin-treated rats was compared with those 
of MCAO-only treated rats. Immunofluorescence results showed a significant 
increase in the percentage of HMGB1-positive cells/DAPI-positive cells in the 
ipsilateral hemisphere of the glycyrrhizin-treated MCAO group (52.17 ± 1.59 %) 
compared with vehicle-treated MCAO group (30.23 ± 1.34 %) (p < 0.001) (Figure 
7A and B).
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Figure 7. Glycyrrhizin inhibits reduction of nuclear HMGB1 immunoreactivity in 
post-ischemic brain. (A) Immunofluorescence results of HMGB1 in brain sections 
of MCAO and/or glycyrrhizin treated rat brain. (B) Quantification plot of 
immunofluorescence results. Number of rats in each group is as follows. 
Sham+vehicle (n = 3), sham+glycyrrhizin (n = 3), MCAO+vehicle (n = 4), 
MCAO+glycyrrhizin (n = 4). ### p < 0.001 versus non-MCAO, non- glycyrrhizin 
group, *** p < 0.001, MCAO without glycyrrhizin group versus MCAO with 
glycyrrhizin group, one-way ANOVA followed by Bonferroni post hoc test.
8. Intracerebroventricular injection of HMGB1 neutralizing antibody is 
protective in ischemic brain injury
Next, I wanted to discern the effect of a more specific inhibition of HMGB1 action 
on ischemic injury; therefore, HMGB1 neutralizing antibody was injected into the 
cerebral ventricle. Five micrograms of HMGB1 neutralizing antibody was injected 
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by infusion pump over 5 min into rats 30 min before the onset of ischemia. After 4
hr of ischemia, the TTC staining results showed HMGB1 neutralizing antibody 
treatment reduced the infarct size of the MCAO-treated rat cortex (Figure 8A and B). 
This result indicates that direct specific blocking by a neutralizing antibody is 
protective on ischemic injury.
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Figure 8. HMGB1 neutralizing antibody reduces infarct volume of post-ischemic 
brain. (A) Representative pictures of TTC staining results. (B) Quantification plot of 
TTC results. Number of rats in each group is as follows. MCAO (n = 4), MCAO + 
neutralizing antibody (n = 8). ** p < 0.01, MCAO without neutralizing antibody 
group versus MCAO with neutralizing antibody group, unpaired t test.
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9. Both therapeutic hypothermia and glycyrrhizin inhibit the gene expression 
of inflammatory cytokines in peri-ischemic brain regions
I then asked whether hypothermia and pharmacological inhibition of HMGB1 
action would have an effect on inflammatory responses evoked in the post-ischemic 
cortex. To measure effects of hypothermia and glycyrrhizin treatment on the 
expression of infarct-modifying cytokines, mRNA levels of four pro-inflammatory 
cytokine genes (IL-1α, IL-1β, IL-6, TNF-α) in the peri-ischemic and ischemic 
region of post-ischemic brain after 4 hr of MCAO were evaluated by real-time PCR. 
As shown in Figure 9, mRNA levels of IL-1β, IL-6, and TNF-α were elevated in 
peri-ischemic regions after ischemia, consistent with previous reports. However, 
theses elevations in mRNA expression by ischemic stimulation were significantly 
attenuated by both therapeutic hypothermia (IL-1β, IL-6, TNF-α) and glycyrrhizin 
treatment (IL-1β, IL-6). I found that therapeutic hypothermia attenuated the 
elevation of gene expression of pro-inflammatory cytokines in peri-ischemic region 
after cerebral ischemia, and pharmacological inhibition of HMGB1 has effects 
similar to that of hypothermia treatment.
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Figure 9. Real-time PCR results of post-ischemic brain tissue. (A) Real-time PCR 
results of IL-1α gene. (B) Real-time PCR results of IL-1β gene. (### p < 0.001,    
# p < 0.05 versus non-MCAO, non-hypothermia group, * p < 0.05, ** p < 0.01, 
*** p < 0.001 one-way ANOVA followed by Bonferroni post hoc test). (C) Real-
time PCR results of IL-6 gene. (### p < 0.001, versus non-MCAO, non-
hypothermia group, *** p < 0.001, * p < 0.05, one-way ANOVA followed by 
Bonferroni post hoc test). (D) Real-time PCR results of TNF-α gene. (## p < 0.01, 
# p < 0.05 versus non-MCAO, non-hypothermia group, *p < 0.05, one-way ANOVA 
followed by Bonferroni post hoc test). Number of rats in each group is as follows. 
Sham (n = 5), sham+hypothermia (n = 5), MCAO (n = 5), MCAO+hypothermia 
(n = 6), MCAO+glycyrrhizin (n = 5).
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Ⅳ. DISCUSSION
In this study, I investigated the effects of therapeutic hypothermia on HMGB1 
release and its role in inflammatory response to cerebral ischemic injury.
First, I compared the sizes of infarct regions in MCAO model rats with or without
hypothermia treatment. The TTC staining is the most widely used method for 
detecting infarct region in MCAO model; therefore, I utilized the TTC staining 
method. TTC staining results demonstrated that therapeutic hypothermia 
significantly attenuated the increase of infarct tissue size in the early stage (4 hr) of 
ischemic injury. Many previous studies have established the protective effect of 
hypothermia in infarct size;51,52 my results, consistent with previous studies, show 
that hypothermia treatment has comparable effects in this specific MCAO 
experimental model.
The ELISA results show that systemic HMGB1 levels were significantly elevated 
at 4 hr after ischemic insult. Consequently, the serum HMGB1 levels from the 
group receiving hypothermia after ischemic injury were reduced to a level almost to 
that of the sham group. A previous study that measured serum HMGB1 levels after 
hypothermia treatment also shows that HMGB1 levels were reduced in a MCAO 
model after hypothermia treatment.53 However, there is one difference between the 
previous study and this study: the previous study used a transient MCAO model and 
I used a permanent MCAO model. The permanent MCAO stroke model mimics 
patients who are not candidates for tPA treatment due to risk factor, or who were 
admitted to the hospital after the therapeutic window for tPA treatment (within 4 to 
6 hr). As described in the introduction, HMGB1 is a prognostic marker in stroke 
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patients. My result suggests that therapeutic hypothermia may be a therapeutic 
options for stroke patients who are not candidates for tPA treatment. More clinical 
studies are required to elucidate the clinical efficacy of hypothermia treatment in 
stroke patients.
To my knowledge, my study is the first to demonstrate that hypothermia inhibits 
the release of HMGB1 from brain cells in the acute stage of ischemia. 
Immunofluorescence was chosen instead of Western blotting because 
immunofluorescence can show exact anatomical location of HMGB1 release. By 
sample preparation method of Western blot, it is difficult to clearly dissociate 
HMGB1 which is in cytoplasm from a locally released extracellular HMGB1. 
Therefore, using immunofluorescence, I also wanted to know subcellular 
distribution of HMGB1 in cortex cells. One report showed that the increase of 
HMGB1 expression after ischemic injury was inhibited after hypothermia 
treatment.53 There are some similarities between the results from this previous study 
and this study; however, there are two important differences. In the previous study, 
brain HMGB1 levels were measured by ELISA assay with a whole brain sample. In 
this study, I used immunofluorescence to show the inhibition of HMGB1 release by 
hypothermia treatment. I believe that this method shows clearly the change of 
HMGB1 release in the MCAO rat model. Both immunofluorescence and ELISA 
results indicate that hypothermia may inhibit the secretion of HMGB1 from the 
ischemic cortex to systemic circulation. 
During sterile injury, like ischemia, HMGB1 is released within 1 hr after ischemia 
as an early mediator of damage and induces later release of several pro-
inflammatory cytokines, such as TNF-α. A previous study demonstrated that 
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HMGB1 is an important mediator in acute systemic immune activation and 
subsequent immune suppression, and that neutralizing HMGB1 action with a 
monoclonal antibody substantially reduced 7 d mortality in a MCAO mice model.28
In this regard, it is worth targeting HMGB1 and the associated signal pathway as a 
potential therapeutic strategy and therapeutic hypothermia as a candidate for new 
adjunctive therapies in the acute stage of ischemic brain injury. Clinical studies for 
clarifying the benefits of hypothermia in stroke patients will be necessary for its 
clinical application.
The present study did not demonstrate whether therapeutic hypothermia 
preferentially blocked the passive release of HMGB1 from necrotic cells, nor the 
active secretion of HMGB1 from major inflammatory cell types. In developing the 
HMGB1 inhibition as therapy in acute stroke, a precise knowledge of release 
mechanisms of HMGB1 is essential. The recently discovered inflammasome is an 
important signaling platform that senses intracellular stress and pathogenic 
microorganisms. After sensing threats, the inflammasome activates the secretion of 
pro-inflammatory cytokines, IL-1β and IL-18.54 Inflammasome signaling is also the 
pathway by which HMGB1 is actively released.55-57 When the actions of 
inflammasome components are inhibited in siRNA treatment or knockout mouse 
models, HMGB1 release is reduced. Activity of inflammasome signaling is 
inhibited by hypothermia treatment in brain trauma injury models.58 However, there 
are no studies investigating the change in inflammasome activity in stroke models 
after hypothermia treatment. Further study will be needed to evaluate the role of 
inflammasome signaling in the inhibition of HMGB1 release by hypothermia.
I next asked which cell type are the main sources of HMGB1 release in ischemic 
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injury, and whether hypothermia could inhibit HMGB1 release from that cell type. 
To answer this question, I co-immunostained the tissue sections with NeuN, a 
widely used neuronal marker, and HMGB1. The results of the immunofluorescence 
showed that about 80 % of cortex cells are HMGB1-positive in the nucleus. After 
MCAO, most HMGB1 was depleted from the cortex. Hypothermia treatment 
reduced the depletion of HMGB1 from ischemic neurons. This result indicates that 
HMGB1 is released more preferentially from neuronal cell types in the ischemic 
cortex 4 hr after the onset of ischemia and hypothermia inhibits this neuronal 
release. Previous report showed that in the acute phase (3 hr after the onset of 
ischemia) of stroke, neurons are more sensitive than other brain cell types to
ischemic injury, which reflects preferential HMGB1 release from neurons.27 Further 
study will be needed to elucidate the specific mechanistic differences between 
neurons and other cell types that lead to preferential release of HMGB1 in neurons.
To evaluate an importance of the inhibition of HMGB1 release in the 
neuroprotective effect of hypothermia on stroke, I measured the effects of a 
pharmacological HMGB1 inhibitor on post-ischemic injury. Glycyrrhizin inhibits 
HMGB1 action pharmacologically by direct binding to the A and B box domains of 
HMGB1.59
The TTC staining results showed that the inhibition of HMGB1 action by 
glycyrrhizin reduced the infarct size significantly compared to vehicle-treated 
MCAO rats. In previous studies, glycyrrhizin treatment reduced the infarct size in 
an MCAO model, which is consistent with my results;24,26 however, I employed a 
permanent MCAO animal stroke model that was not used in previous studies.
Therefore, my results are more clinically relevant to most stroke patients who are 
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not the candidates for thrombolysis.
The immunofluorescence results showed that HMGB1 release from the ischemic 
cortex was inhibited by hypothermia treatment. This result was not expected by the 
direct binding mechanism of glycyrrhizin when performing the experiment. 
However, a previous study reported that glycyrrhizin reduced the HMGB1 release 
in the ischemic cortex and suggested that glycyrrhizin blocks translocation of 
HMGB1 from the nucleus to the cytoplasm by inhibiting the phosphorylation of 
HMGB1.26 This mechanism may explain the reduction in HMGB1 release by 
glycyrrhizin in my results.
Previous studies regarding the effects of glycyrrhizin were performed in transient 
MCAO models, and the effect of glycyrrhizin was assessed in subacute or chronic 
stages.24,26 As mentioned in the introduction, permanent occlusion models properly 
represent the majority of stroke patients who are not candidates for thrombolytic 
therapy (tPA).11 The present study shows that glycyrrhizin was able to ameliorate 
ischemic damage by inhibiting the HMGB1 actions, and by blocking the 
extracellular HMGB1 secretion in the acute ischemic stage of a more clinically 
relevant permanent MCAO model. The acute effects of glycyrrhizin on this MCAO 
model suggest that it may be an effective therapy for acute stage stroke patients. 
Further clinical studies with ischemic stroke patients will be needed for elucidating 
clear benefits of glycyrrhizin treatment in clinical application.
Glycyrrhizin was used as the pharmacologic inhibitor against HMGB1 action to 
clarify the current discrepancy in effects of neutralizing antibodies on infarct size in 
MCAO models. However, glycyrrhizin is a chemical inhibitor that may possibly 
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have effects other than direct inhibition of HMGB1 action. For example, my 
immunofluorescence results showed that glycyrrhizin has effects on HMGB1 
release from the ischemic cortex beyond direct HMGB1 binding. To evaluate the 
more specific effects of HMGB1 inhibition in my MCAO model, HMGB1 
neutralizing antibody was injected intracerebroventricularly in the MCAO rats.
Intracerebroventricular injection was used to induce direct access of neutralizing 
antibodies to the infarct brain region. Between blood vessels and the brain 
parenchyma is the blood-brain barrier, which can block the access of antibody or 
drug to the target brain region. The discrepancy in previous studies with HMGB1 
neutralizing antibody may be derived from this obstacle. Hence, the neutralizing 
antibody was applied directly into the brain by intraventricular injection and its 
effects were measured by TTC staining. The TTC staining results showed that 
HMGB1 neutralizing antibody treatment reduced the increase of infarct size in the 
MCAO model. This result indicates that specific direct inhibition of HMGB1 action 
is protective in ischemic injury, and more clearly demonstrates that HMGB1 is an 
important mediator in stroke pathophysiology.
The elevation of inflammatory cytokine gene expression by HMGB1 is important 
in inducing brain tissue damage in stroke. Real-time PCR results demonstrate that 
the expressions of many inflammatory cytokines (IL-1β, IL-6, TNF-α) were 
elevated after ischemic injury in the peri-ischemic region, specifically. 
Several previous reports have shown the elevation of inflammatory cytokines in 
ischemic brain;60,61 therefore, this real-time PCR results are consistent with previous 
reports. My results also show that hypothermia or pharmacological HMGB1 
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inhibition reduces the elevations of inflammatory cytokine genes. This suppressive 
effect of hypothermia on expressions of inflammatory cytokines after ischemic 
injury was reported previously.62-64 It is surprising that the pharmacological 
inhibition of HMGB1 has an effect on inflammatory cytokine gene expression 
comparable to hypothermia treatment which is the most promising neuroprotectant. 
Previous studies using in vivo and in vitro models demonstrated that glycyrrhizin 
reduces elevated inflammatory cytokine expressions after neuronal injury.26,65,66
Hence, my results are consistent with previous reports; however, there are 
differences between the sample preparation paradigms.
Most previous studies have shown the effects of hypothermia on inflammatory 
cytokine levels, and mRNA or protein levels of inflammatory cytokines were 
measured in whole ischemic hemisphere samples. The effect of hypothermia on 
clinically relevant peri-ischemic regions that mimic the ischemic penumbra was not 
properly evaluated. I prepared tissue samples from three regions of each rat brain 
that were categorized as ischemic regions, peri-ischemic regions, and the 
contralateral regions. In particular, the peri-ischemic regions were defined according 
to the detected perfusion-diffusion mismatch regions in MCAO rats.67 This findings 
suggest that the effect of hypothermia on inflammatory cytokine expressions in 
peri-ischemic regions is an important mechanism in the neuroprotection of 
hypothermia, and that blocking HMGB1 action has similar effects to hypothermia.
There is a discrepancy between the effects of hypothermia and glycyrrhizin on 
TNF-α gene expression. Hypothermia attenuated elevated expressions of TNF-α in 
peri-ischemic regions of ischemic brain, but glycyrrhizin did not. In previous study, 
mRNA expression of TNF-α was more sensitive to HMGB1 treatment than that of 
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IL-1β, therefore was reached to a maximal level with lower level of HMGB1.25
Difference between the sensitivities of these two cytokine expressions in response 
to HMGB1 may explain the discrepancy described above. The concentration of 
glycyrrhizin that was used in this study may have been insufficient for complete 
blocking of HMGB1 signaling, as shown by hypothermia.
In this study, hypothermia was induced 15 min after MCA occlusion and 
glycyrrhizin and neutralizing antibody were injected 30 min before MCA occlusion. 
However, in clinical situation, hypothermia or therapeutics cannot be treated in this 
time phase for stroke patients. To evaluate the possibility of clinical application of 
hypothermia and glycyrrhizin as neuroprotectant in ischemic stroke, hypothermia 
treatment and injection of neutralizing antibody or glycyrrhizin should be started, 
more than 1 hr after MCA occlusion. Further study will be needed to verify the 
effects of hypothermia and glycyrrhizin or neutralizing antibody injection in more 
clinically relevant time phases of stroke model.
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Ⅴ. CONCLUSIONS
I designed this study to investigate the importance of HMGB1 action in the 
neuroprotection of therapeutic hypothermia and the inflammatory role of HMGB1 
in the propagation of ischemic damage.
1. TTC staining result showed that after 4 hr of mild hypothermia (33°C) 
treatment, the increase of infarct size in MCAO rat was reduced.
2. The immunohistochemistry results demonstrated that hypothermia 
attenuated the reduction of HMGB1-positive cells in the ischemic cortex.
3. The ELISA results showed that hypothermia reduced the increase in 
serum HMGB1 levels in MCAO rats.
4. The TTC staining results showed that intraperitoneal injection of 
glycyrrhizin inhibited the increase of infarct size in the ischemic cortex.
5. The immunofluorescence analysis showed that glycyrrhizin reduced 
depletion of HMGB1 in the ischemic cortex.
6. The TTC staining results showed that HMGB1 neutralizing antibody 
inhibited the increase of infarct size in the MCAO-treated rat cortex.
7. The real-time PCR results showed that hypothermia and glycyrrhizin 
reduced the elevation of inflammatory cytokine gene expression (IL-1β, 
IL-6, TNF-α) in peri-ischemic regions of the MCAO-treated rat cortex.
The current study presented that therapeutic hypothermia attenuates ischemic 
damage by inhibition of extracellular HMGB1 release and HMGB1-induced
inflammatory cytokine expressions in the post-ischemic cortex.
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ABSSTRACT (IN KOREAN)
뇌경색에 대한 저체온요법의 치료효과와 관련된 염증기전의 규명
<지도교수 김 철 훈>
연세대학교 대학원 의과학과
이 정 호
허혈성 뇌경색에서 염증반응은 뇌경색에 의해 손상받는 부위가 시간이
지남에 따라 확장되는 현상에 관여하며, 뇌경색의 중증도를 결정하는데
있어 중요하다. 치료적 저체온요법은 현재 신경손상을 막는 가장 유망한
치료법으로 알려져 있지만, 신경보호를 일으키는 기전은 확실하게
알려져 있지 못하다. 이 연구에서는, 치료적 저체온증이 허혈성 세포
손상시 분비되는 염증성 사이토카인인 high mobility group box 1
(HMGB1)의 분비를 줄이고, 허혈성 뇌손상에 대한 염증반응의 활성화를
막는다는 가설을 증명하고자 하였다. 연구결과에 의하면, 저체온은
중뇌동맥 폐쇄를 통해 쥐에서 뇌경색과 유사한 상황을 유도한
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동물모델에서 뇌경색에 의한 손상부분의 크기를 줄였다. 면역염색화학
분석법과 효소면역측정법(ELISA)을 사용하여 실험한 결과에서, 
저체온증은 high mobility group box 1이 뇌경색에 의해 손상받은
뇌부위에서 순환계로 분비되는 과정을 억제하였다. 또한 real-time PCR로
실험한 결과, 저체온증은 뇌경색이 일어난 뇌부위, 그 중에서도 특별히
peri-ischemic region에서 뇌경색 부위가 시간이 지남에 따라 커지는 데에
중요한 기전으로 알려진 염증성 사이토카인의 유전자발현을 줄였다. High 
mobility group box 1에 직접적으로 결합하여 그 작용을 억제하는 약물인
glycyrrhizin를 뇌경색 동물모델에 투여했을 때에도 저체온증과 유사한
염증성 사이토카인에 대한 효과를 보였다. 결론적으로 이 연구는
저체온증이 high mobility group box 1의 분비를 줄이고, 이에 의해 염증성
사이토카인 발현의 활성화를 억제하는 것을 보였다. 이 연구를 통해
저체온증이 뇌경색에서 보이는 신경보호에서 high mobility group box 1이
중요하게 관련되어 있음을 보였다.
핵심되는 말: 뇌경색, 저체온증, 염증, 사이토카인
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